Internet entrepreneur Michael Greve commits $10 million to SENS related research and startups including a $5 million donation over 5 years to SENS Research Foundation

Michael Greve

German Internet Entrepreneur Michael Greve today announced that his Forever Healthy Foundation will be committing $5 Million in philanthropic support over the next five years to the SENS Research Foundation (SRF), a non-profit organization focused on transforming the way the world researches and treats age-related disease.

​In addition Michael Greve’s company KIZOO Technology Ventures will be committing seed investments of $5 million in startups focused on bringing rejuvenation biotechnology treatments to market.

​“My goal is to provide support for the critical research of the SENS Research Foundation and to facilitate the development of the rejuvenation biotech industry and ecosystem. I think we should have more people contribute to the step-by-step creation of cures for the root causes of all age-related diseases."

"And we should have a whole rejuvenation industry based on the SENS treatment model including the self-accelerating feedback-loop of success stories and amazing opportunities for scientist, entrepreneurs and VC investors. This will truly accelerate both research and therapies. I have decided to lead by example and make this $10 million commitment,” said Michael Greve.

Forever Healthy Foundation’s initial donation will fund projects including Allotopic Expression of Mitochondrial Genes led by Dr. Matthew O’Connor at the SENS Research Foundation Research center and Pharmacological and/or enzymatic cleavage of glucosepane crosslinks led by Dr. David Spiegel at Yale University, SENS Research Foundation’s Education Program led by Dr. Greg Chin and other SENS Research Foundation programs.

“Michael Greve’s commitment shows that there is clear support for the critical work of the SENS Research Foundation.  As the first donation in our Project|21 fundraising campaign, it will help enable us to build a bridge to the first human clinical trials of Rejuvenation Biotechnologies by 2021. This gift is an important cornerstone that we will be able to build upon,” said Mike Kope, CEO, SENS Research Foundation.

For more information on the SENS Research Foundation visit sens.org